DIR fees still mauling margin. PBM contracts tighter every cycle. About 40% of U.S. independent pharmacy owners were licensed before 2010, and the buyer universe is consolidating faster than the seller universe. The next 36 months decide who sells from strength.
Start with a 15-minute call · NDA first · no prep neededThe pharmacies that sell well in 2030 are the ones whose owners started preparing in 2027.
Standard PBM contracts compress every year. DIR true-ups still surprise at year-end, even after the 2024 structural changes. The pharmacies still earning premium multiples have one of three things: 340B contract pharmacy revenue, defensible specialty or LTC mix that PBMs can't squeeze the same way, or a strategic buyer relationship from pre-2024.
Five active buyer categories, in rough order of deal volume:
Roughly 40% of U.S. pharmacy owners were licensed before 2010. That cohort moves over the next decade. When seller supply spikes, multiples for everyone soften — even for the prepared ones. Going to market in 2027 is structurally different from going to market in 2030.
The owners who get strong multiples in the next five years share three traits: clean license transferability, defensible specialty or 340B revenue, and operational independence from day-to-day Rx work. The work to get there takes 18-36 months. Starting six months before listing is too late.
State-level operators absorbing $5-30M deals. Typically the most realistic buyer pool for owner-operators outside major metros. Pay below specialty multiples but close faster and with less DEA-transfer drama.
Cardinal Health's independent network, McKesson Health Mart, AmerisourceBergen Good Neighbor. They've shifted from outright acquisition to network membership in many markets, but full buyouts still happen — especially in priority geographies.
PE-backed platforms paying premium multiples for specialty pharmacy revenue: Shields Health Solutions, BrightSpring's PharMerica, regional specialty platforms. Best fit if your specialty mix is documented and your payor contracts are clean.
Buyers acquiring specifically for FQHC and DSH contract pharmacy revenue. Highly specialized diligence — they care about the consent letter language, the covered entity's tenure, and the volume trend over 24 months.
Long-term care channel buyers with their own multiple band, often higher than retail. The economics are different enough that LTC mix should be marketed separately if it's more than 20% of revenue.
Mostly active sub-$1M, where SBA financing makes a clean acquisition viable. Largely priced out at the upper end. Useful as floor-setters in an auction process.
We review your last 24 months of financials, payor mix, DIR exposure, and license/contract status. You get a clear range based on what specialty, LTC, and 340B-focused buyers are paying in your geography for businesses your size. No engagement, no obligation. The output is a written valuation memo, not a sales pitch.
We approach qualified buyers across regional consolidators, strategic chains, specialty roll-ups, 340B-focused buyers, and LTC operators. Outreach happens under NDA, before you're publicly listed. Strongest offers come to owners who aren't visibly shopping — competitive process, not desperate listing.
We run LOI, due diligence, and PSA negotiation alongside your attorney and accountant. The pharmacy-specific work — DEA application timing, state board approvals, 340B consent letters, working capital peg with DIR true-up reserves — gets sequenced so close doesn't slip 60 days because of paperwork. Every term gets explained before you sign.
Independent retail pharmacies on standard PBM contracts trade at roughly 0.20-0.35× revenue, or 4-5× SDE. Pharmacies with meaningful 340B contract pharmacy revenue, LTC mix, or specialty volume can earn 4-7× SDE depending on payor stability and buyer fit. The single biggest swing factor is your gross margin trend over the last 24 months.
18-36 months before you actually want to close. The work that drives multiple — separating yourself from day-to-day operations, cleaning up DIR true-up reserves, organizing specialty contract documentation — takes that long to do right. Starting six months out is the difference between a 4× exit and a 5.5× exit.
Five buyer types, roughly ordered by deal volume: regional independent consolidators (state-level, $5-30M deals), strategic chains (Cardinal Health Independent Network, McKesson Health Mart, AmerisourceBergen Good Neighbor), specialty pharmacy roll-up platforms (typically PE-backed), 340B-focused buyers chasing FQHC contracts, and LTC-focused buyers. Individual operators still buy at the small end but have largely been priced out of the $1M+ range.
DIR true-ups that aren't reserved on your balance sheet show up as a working capital surprise in diligence and almost always trigger a retrade. Buyers want 18-24 months of DIR data, normalized for the 2024 structural changes. Pharmacies that get clean diligence pre-reserve aggressively and document the calculation. The ones that don't lose 5-15% of headline price.
DEA registration does not transfer with an entity sale. The buyer must apply for a new DEA registration tied to the new owning entity, and the timing of that approval is one of the most-missed risks in pharmacy M&A. Same for state board licensure. We sequence the application timing so close doesn't slip 60 days because of paperwork.
340B contract pharmacy revenue is gold to specialty buyers, but only if the FQHC or covered entity contracts are transferable and properly documented. The covered entity has the right to terminate or renegotiate at change of control. Get the consent letter language reviewed before you go to market — not in week three of diligence.
9-14 months from engagement to close, assuming clean books and a defined buyer universe. Pre-engagement preparation (18-36 months) is separate. The deal itself: roughly 4-8 weeks of CIM development and outreach, 6-10 weeks of LOI and due diligence, 8-12 weeks from signed PSA to close.
Most buyers want a 12-24 month transition with the seller staying on as Pharmacist-in-Charge or in a clinical role, especially when patient relationships are concentrated. The structure varies — earnout tied to retention, employment agreement, or consulting role. The cleanest exits are owners who started reducing patient-facing time 12-18 months before sale.
A Quality of Earnings (QoE) is a third-party normalized P&L that buyers use to underwrite the transaction. Above $5M EBITDA, every credible buyer requires one. Below that, seller-prepared financials sometimes work if they're clean. Buyer-paid QoE is the norm at $5M+; on smaller deals, who pays gets negotiated.
Two differences. We use proprietary data infrastructure to surface qualified buyers across the full national universe, not just the 6-10 names a regional broker keeps in their rolodex. And we represent owners exclusively — never buyers — so when we negotiate, our incentive isn't split between getting your deal closed and keeping a buyer relationship for next year.
No prep on your end. NDA before any specifics get discussed. The output is a written valuation range based on your geography, payor mix, and operator profile — not a sales pitch.
Request a confidential conversation